Neotropix has a novel drug discovery platform and a new oncolytic virus that overcomes many of the hurdles posed by current therapies, particularly those derived from adenovirus, which suffers from drawbacks that are difficult to circumvent.

Neotropix is confident that its cancer-killing virus will have greater efficacy and less toxicity than any therapy available today for small-cell lung cancers and cancers with high unmet medical needs.

Some of the most critical features offered through Neotropix products are:

• Critical systemic administration

• Enhanced stability in serum

• Relevant animal models

• A high therapeutic index

• A simple, malleable genome and rapid life cycle

• Demonstrated effectiveness in vivo

• An acceptable safety profile in preliminary studies

The NTX virus has undergone extensive in vitro and in vivo testing. The pre-clinical studies for the native virus as an oncolytic therapy are in advanced stages of completion.